VYGR on Nasdaq

Voyager Therapeutics (United States)

Logo: voyagertherapeutics.com3

We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases.5 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

2013Founded1

Compare with Editas Medicine, SANGAMO THERAPEUTICS, INC or Kymera Therapeutics, or pick any stock.

  • TickerVYGR on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersCambridge1
  • Websitewww.voyagertherapeutics.com
  • Incorporated inDE4
  • Business address75 Hayden Avenue, Lexington, Ma 024214
  • Filer categoryAccelerated filer, Smaller reporting company4
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of our programs are derived from our TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which we have used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Some of our programs are wholly-owned, and some are advancing with licensees and collaborators, including Alexion, AstraZeneca Rare Disease, or Alexion; Novartis Pharma AG, or …5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-326.6%Operating margin6
-296.5%Net margin6
-49.5%Revenue growth, 20256
-61.1%Return on equity6
-$135.1MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$134.7M
  • Income tax0¢$144.0K

Out of $40.4M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$40.4M in 2025−61% since 2019
0$100.0M$200.0M$300.0M2019: $104.4M$104.4M20192020: $171.1M$171.1M2020+64%2021: $37.4M$37.4M2021−78%2022: $40.9M$40.9M2022+9%2023: $250.0M$250.0M2023+511%2024: $80.0M$80.0M2024−68%2025: $40.4M$40.4M2025−50%
Operating income789106-$131.8M in 2025+155% since 2019
-$200.0M-$100.0M0$100.0M$200.0M2019: -$51.7M-$51.7M20192020: $27.4M$27.4M20202021: -$73.6M-$73.6M20212022: -$50.8M-$50.8M2022−31%2023: $122.0M$122.0M20232024: -$83.3M-$83.3M20242025: -$131.8M-$131.8M2025+58%
Net income789106-$119.7M in 2025+175% since 2019
-$200.0M-$100.0M0$100.0M$200.0M2019: -$43.6M-$43.6M20192020: $36.7M$36.7M20202021: -$71.2M-$71.2M20212022: -$46.4M-$46.4M2022−35%2023: $132.3M$132.3M20232024: -$65.0M-$65.0M20242025: -$119.7M-$119.7M2025+84%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Collaboration revenue$40.4M$80.0M$250.0M
Research and development$134.7M$127.4M$92.2M
General and administrative$37.5M$35.9M$35.8M
Total operating expenses$172.2M$163.3M$128.0M
Operating (loss) income-$131.8M-$83.3M$122.0M
Interest income$10.6M$18.3M$11.7M
Other income$1.6M$622.0K$3.0K
Total other income, net$12.3M$18.9M$11.7M
(Loss) income before income taxes-$119.6M-$64.3M$133.7M
Income tax provision$144.0K$665.0K$1.4M
Net (loss) income-$119.7M-$65.0M$132.3M
Net unrealized gain (loss) on available-for-sale-securities$439.0K-$359.0K$171.0K
Total other comprehensive income (loss)$439.0K-$359.0K$171.0K
Comprehensive income (loss)-$119.3M-$65.4M$132.5M
Net (loss) income per share, basic (in dollars per share)-$2.04-$1.13$3.08
Net (loss) income per share, diluted (in dollars per share)-$2.04-$1.13$2.97
Weighted-average common shares outstanding, basic (in shares)58.7M shares57.7M shares43.0M shares
Weighted-average common shares outstanding, diluted (in shares)58.7M shares57.7M shares44.6M shares

Compare Voyager Therapeutics (United States) with another company

Leadership

Who has led Voyager Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andre Turenne2018–2021
  2. Alfred Sandrock2022–now

President

  1. Andre Turenne2018–2021
  2. Alfred Sandrock2022–now

Chief financial officer

  1. Jeff Goater2016
  2. Jane Henderson2017–2018
  3. Allison Dorval2018–2021
  4. Peter P. Pfreundschuh2022–2024
  5. Nathan D. Jorgensen2024–now

Chief operating officer

  1. Matthew P. Ottmer2017–2020
  2. Robin Swartz2022–now
201520202025
Board members and other officers (26)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerJacquelyn Fahey Sandell named Jan 17, 202448
  • DirectorMichael Higgins named Mar 3, 2023 to Jan 17, 202448

Timeline

  1. Mar 23, 2022New chief executive Alfred Sandrock becomes CEO14
  2. Jul 18, 2018New chief executive Andre Turenne becomes CEO15
  3. 2013Founded Founded1

Filings

356 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 170 insider forms, 31 large holders, 2 private raises, 76 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. Aug 6, 20268-K EDGAR
  3. Aug 6, 202610-Q EDGAR
  4. Jul 31, 2026SCHEDULE 13G/A EDGAR
  5. Jul 13, 20268-K EDGAR
  6. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  7. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  10. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Jun 11, 20264 OWNERSHIP DOCUMENT EDGAR
  15. Jun 10, 20268-K EDGAR
  16. Jun 1, 20268-K EDGAR
  17. May 18, 20263 OWNERSHIP DOCUMENT EDGAR
  18. May 15, 2026144 EDGAR
  19. May 15, 2026144 EDGAR
  20. May 15, 2026SCHEDULE 13G/A EDGAR

The 356 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

85 open-market trades by officers, directors and large owners since October 2021: 3 buys and 82 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 2, 2026Sandrock AlfredPresident and CEOSale11,511$3.87$44.5KForm 4
Feb 24, 2026Swartz RobinCOO & CBOSale6,458$3.77$24.3KForm 4
Feb 24, 2026Sandrock AlfredPresident and CEOSale14,197$3.79$53.8KForm 4
Feb 24, 2026Jorgensen Nathan D.Chief Financial OfficerSale4,668$3.77$17.6KForm 4
Feb 24, 2026Carter Todd AlfredChief Scientific OfficerSale4,174$3.76$15.7KForm 4
Feb 18, 2026Swartz RobinCOO & CBOSale3,882$3.44$13.4KForm 4
Feb 18, 2026Carter Todd AlfredChief Scientific OfficerSale3,301$3.44$11.4KForm 4
Feb 18, 2026Sandrock AlfredPresident and CEOSale11,732$3.41$40.0KForm 4
Feb 10, 2026Swartz RobinCOO & CBOSale4,569$3.85$17.6KForm 4
Feb 10, 2026Sandrock AlfredPresident and CEOSale12,192$3.78$46.1KForm 4
Feb 10, 2026Carter Todd AlfredChief Scientific OfficerSale3,525$3.85$13.6KForm 4
Oct 3, 2025Jorgensen Nathan D.Chief Financial OfficerSale7,666$4.78$36.6KForm 4
Aug 18, 2025Ferguson TobyChief Medical OfficerSale19,000$3.73$70.9KForm 4
Apr 2, 2025Ferguson TobyChief Medical OfficerSale10,086$3.43$34.6KForm 4
Apr 2, 2025Sandrock AlfredPresident and CEOSale10,885$3.43$37.3KForm 4
Feb 20, 2025Carter Todd AlfredChief Scientific OfficerSale3,305$4.26$14.1KForm 4
Feb 20, 2025Sandrock AlfredPresident and CEOSale11,702$4.24$49.6KForm 4
Feb 20, 2025Swartz RobinCOO & CBOSale3,894$4.25$16.6KForm 4
Feb 11, 2025Carter Todd AlfredChief Scientific OfficerSale5,413$4.45$24.1KForm 4
Feb 11, 2025Swartz RobinCOO & CBOSale6,950$4.45$30.9KForm 4

All 85 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 3, 2024Raised $20 million in a private offering of equity Form D: 1 investor so far Form D
  2. Feb 23, 2023Raised $39 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.5,172,063$18.1M0.0%−396,318
Millennium Management LLC4,442,951$15.6M0.0%+1,014,380
Armistice Capital, LLC3,436,000$12.0M0.3%−64,000
Vestal Point Capital, LP2,625,000$9.2M0.2%−377,936
Vanguard Capital Management LLC2,345,674$8.2M0.0%+62,421
Geode Capital Management, LLC1,330,492$4.7M0.0%+280,514
Opaleye Management Inc.1,185,000$4.1M0.4%+35,000
State Street Corp1,076,422$3.8M0.0%+128,196
Two Sigma Investments, LP948,517$3.3M0.0%+332,857
Dimensional Fund Advisors LP838,184$2.9M0.0%−37,384
Vanguard Portfolio Management LLC810,091$2.8M0.0%+84,322
Citadel Advisors LLC784,067$2.7M0.0%+419,403
Morgan Stanley697,334$2.4M0.0%+15,623
Erste Asset Management GmbH638,900$2.3M0.0%−456,241
Renaissance Technologies LLC495,236$1.7M0.0%−82,788
Sphera Funds Management Ltd.427,554$1.5M0.2%−42,207
Diadema Partners LP413,642$1.4M0.5%−10,000
Northern Trust Corp411,803$1.4M0.0%+26,960
Aqr Capital Management LLC356,109$1.2M0.0%+123,428
Goldman Sachs Group Inc338,477$1.2M0.0%−89,120
Vanguard Fiduciary Trust Co337,325$1.2M0.0%+39,003
Fiduciary Trust Co334,397$1.2M0.0%No change
Jpmorgan Chase & Co276,211$988.8K0.0%−656
Point72 Asset Management, L.P.236,083$826.3K0.0%−32,140
Panagora Asset Management Inc231,077$808.8K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54